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Abstract
Adiponectin is an anti-atherogenic adipokine that inhibits the development of plaque by mechanisms that are not
completely understood. Extracellular matrix (ECM) may have a role in the pathogenesis of atherosclerosis. We explored the
effect and mechanisms of adiponectin on the synthesis of prolyl-4-hydroxylase (P4H) in interleukin 6 (IL-6)-stimulated
human aortic smooth muscle cells (HASMCs). P4Ha1 mRNA level was quantified by RT-PCR, the protein levels of
phosphorylated extracellular signal-regulated kinase 1/2 (ERK1/2) and P4Ha1 were quantified by western blot analysis, and
activation of specific protein 1 (Sp1) was determined by electrophoretic mobility shift assay and subcellular localization of
Sp1 by immunofluorescence analysis. Adiponectin significantly increased P4Ha1 mRNA and protein levels in IL-6-stimulated
HASMCs in a dose- and time-dependent manner. As well, ERK1/2 and Sp1 played a crucial role in the effect of adiponectin
upregulating P4Ha1 expression in IL-6-stimulated HASMCs. Adiponectin abrogated the effects of IL-6 on collagen III level,
which may indicate that P4Ha1 is essential for folding the procollagen polypeptide chains into stabilized collagen.
Adiponectin attenuates IL-6–inhibited P4Ha1 synthesis and stabilizes collagen formation in HASMCs through a Sp1-ERK1/2-
P4Ha1-dependent pathway.
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Introduction
Experimental results have demonstrated that the pathogenesis
of atherosclerosis is based on several mechanisms. Extracellular
matrix (ECM) may have a role in the pathogenesis of
atherosclerosis [1]. ECM components, especially collagen, are
thought to be important in the progression of atherosclerosis.
Prolyl-4-hydroxylase (P4H) is a key intracellular enzyme essential
for all known types of collagen maturation and secretion [2].
During collagen posttranslational processing, P4Ha1 folds the
procollagen polypeptide chains into stable triple helical molecules
[3]. Inhibition of P4H can decrease the level of collagen [4]. P4H
is regulated by various cytokines, including tumor necrosis factor
a, transforming growth factor b, and interleukins (ILs) [5]. Among
them, IL-6 is one of the most potent cytokines involved in
cardiovascular pathogenesis and actively regulates ECM metab-
olism [6]. Adiponectin is an adipocyte-specific plasma protein,
has anti-inflammatory properties and might regulate ECM
metabolism.
The promoter of P4Ha1 possesses several functional enhancer
element-binding sites, including specific protein 1 (Sp1), NonO
and hnRNP-K sites [7]. Sp1 is one of the first eukaryotic
transcription factors to be identified and cloned [8]. It plays an
important role in the transcriptional regulation of ECM
metabolism. Previous work has shown that mutations in the
Sp1-binding sites of the TbRE are associated with low collagen
expression [9]. Although accumulating data have demonstrated
that cytokines might decrease P4Ha1 expression through
pathways leading to the activation of nuclear proteins, little is
known about the defense molecules – responsive cis-elements – of
the P4Ha1 transcriptional promoter.
Intracellular signaling transduction pathways activated by
cytokines are mitogen-activated protein kinase (MAPK) pathways,
of which there are 3 distinct groups: extracellular signal-regulated
kinase (ERK), Jun N-terminal kinase, and p38 MAPK. ERK is
most associated with the biological effect of inflammation,
adiponectin and ECM metabolism. Some studies demonstrated
that inflammation and adiponectin are involved in the ERK1/2
pathway. Other studies demonstrated that ECM metabolism is
also involved in the pathway [10]. Sp1, as a vital downstream
molecule in the MAPK pathway, can be activated by ERK to
induce the DNA binding activity[11].
We aimed to investigate whether adiponectin can upregulate
P4Ha1 expression in IL-6-stimulated human aortic smooth muscle
cells (HASMCs) and to elucidate the corresponding mechanisms to
find novel approaches to the management of cardiovascular risk.
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Materials
HASMCs, cell culture medium and supplements were from Cell
Science (Carlsbad, CA, USA). Recombinant human IL-6 was
from R&D Systems (Minneapolis, MN, USA). Antibodies against
P4Ha1 and Sp1 were from Abcom (Cambridge, MA, USA).
Antibodies against phosphor-ERK1/2 and b-actin were from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). PD98059 was
from Biosource (Camarillo, CA, USA). WP631 was from Alexis
Biochemicals (San Diego, CA, USA). All other chemicals were of
the highest grade commercially available.
Cell Culture
HASMCs were cultured in smooth muscle cell culture medium
up to passage 4. In all experiments, HASMCs were incubated in a
humidified incubator at 37uC in a 95% air-5% CO2 atmosphere
until cells reached 80%–90% confluence and were rendered
quiescent by serum-free starvation for at least 24 h. HASMCs
were stimulated with IL-6 in the presence or absence of 10
multiplicities of infection (MOI) of adiponectin adenovirus
(Invitrogen, Carlsbad, CA, USA) for 8 hr. HASMCs were
pretreated with 20 mM of the ERK inhibitor PD98059 or
0.1 mM of the Sp1 inhibitor WP631 for 1 hr.
RT-PCR Analysis
After stimulation with 20 ng/ml IL-6 for 24 hr, RNA from
cultured HASMCs was extracted with use of TriZol (Invitrogen,
Carlsbad, CA, USA) following the manufacturer’s protocol.
Purified RNA was reverse-transcribed into cDNA (RevertAid M-
MulV Reverse Transcriptase, Fermentas UAB, Mainz, Germany).
Aliquots of the reverse-transcribed mixture underwent PCR with
specific primers as described [12]. Results from quantitative real-
time PCR were analyzed by use of the 7500 Real-Time PCR
System (Applied Biosystems, Foster City, CA, USA). Results were
controlled for real-time efficiency and normalized with those for
b-actin.
Western blot analysis
After stimulation with 20 ng/ml IL-6, cell lysates from cultured
HASMCs were prepared with use of lysis buffer. Equal amounts of
lysates were run on 14% poly-acrylamide gel, transferred onto
nitrocellulose membranes (Bio-Rad, Hercules, CA, USA) and
incubated at 4uC overnight with the primary antibodies mouse
anti-b-actin (Santa Cruz Biotechnology; 1:1000 dilution), goat
anti-P4Ha1 (Abcom; 1:250) or rabbit anti-phospho-specific p44/
42 MAPK (Thr202 and Tyr204) (Santa Cruz Biotechnology;
1:250). The blots were then incubated with peroxidase-conjugated
secondary antibodies (Santa Cruz Biotechnology; 1:2000 dilution)
at room temperature for 2 hr, and membranes underwent
detection by enhanced chemiluminescence plus reagents (Milli-
pore, Billerica, MA, USA).
Electrophoretic mobility shift assay (EMSA) of Sp1
Briefly, cultured HASMCs were pretreated with WP631 for
1 hr, then stimulated with 20 ng/ml IL-6 for 1 hr. Nuclear
extracts were prepared (Active Motif, Carlsbad, CA, USA); the
nuclear fraction was transferred into a pre-chilled microcentrifuge
tube and stored at 280uC until use. The protein concentration of
the cell extract was measured by the Bradford assay (Bio-Rad,
Hercules, CA, USA). Activation of Sp1 was determined by EMSA
(Roche, Madison, WI, USA) according to the manufacturer’s
instructions. The generated chemiluminescent signals were
recorded on an imaging device.
Immunofluorescence
Subcellular localization of Sp1 was determined by immunoflu-
orescence analysis. Cultured HASMCs were pretreated with the
Sp1 inhibitor WP631 or ERK inhibitor PD98059 for 1 hr before
stimulation with 20 ng/ml IL-6 for 1 hr. Then cells were fixed
with paraformaldehyde. Permeabilized cells were stained by direct
immunofluoresence with a FITC-conjugated monoclonal antibody
against Sp1 (1:100 dilution). Inclusion-containing cells were
visualized under a light fluorescent microscope (Olympus, Japan)
and a Bio-Rad MRC 600 confocal laser scanning microscope (Bio-
Rad, Hercules, CA).
ELISA
Cultured HASMCs were pretreated with WP631 or PD98059
for 1 hr. After stimulation with 20 ng/ml IL-6 for 24 hr, the levels
of type I and III procollagen and collagen secreted from HASMCs
were quantified by ELISA (R&D Systems) according to the
manufacturer’s recommended protocols.
Statistical Analysis
Data are presented as mean6SD. Statistical analyses involved
ANOVA with subsequent Scheffe t test. A P,0.05 was considered
statistically significant.
Results
1. Effect of dose and time of IL-6 stimulation on P4Ha1
expression
To explore the effect of IL-6 on the expression of P4Ha1,
HASMCs were treated with different doses of recombinant human
IL-6 and for different times before being harvested for measure-
ment of P4Ha1 mRNA and protein levels. The expression of
P4Ha1 was lowest at 20 ng/ml IL-6 and at 24 hr (Figure 1).
2. Effect of dose and time of adiponectin on P4Ha1
expression
IL-6–stimulated HASMCs were treated with various MOI of
adiponectin adenovirus for different times before being harvested
for measurement of P4Ha1 mRNA and protein levels. The
mRNA and protein expression of P4Ha1 peaked at 10 MOI
adiponectin and at 8 hr (Figure 2).
3. Sp1 regulates the effect of adiponectin upregulating
P4Ha1 expression in IL-6-stimulated HASMCs
3.1 Effect of adiponectin on Sp1 activation induced by IL-6
in HASMCs. IL-6 significantly upregulated the binding activity
of Sp1 in HASMCs as compared with control cells (P,0.05;
Figure 3A). Adiponectin alone had no effect on the binding activity
of the Sp1 in HASMCs, but it inhibited the IL-6-induced binding
activity of Sp1 by 60% (P,0.05). Treatment with WP631, an
inhibitor of Sp1, inhibited the IL-6 induced binding activity of Sp1
by 95% (P,0.05). The combination of WP631 and adiponectin
abrogated the Sp1 binding activity induced by IL-6 by 90%
(P,0.05), whereas adiponectin or WP631 alone did not affect Sp1
binding activity (P.0.05).
3.2 Effect of Adiponectin on Subcellular Localization and
Expression of Sp1 Induced by IL-6 in HASMCs. Most
unstimulated cells showed diffuse staining in the cytoplasm, as well
as weak staining in the nucleus, under normal growth conditions
(Fig. 3B). With IL-6 treatment for 1 hr, staining for Sp1 in the
nucleus was eight-fold higher than that in control cells (P,0.05).
Eight hours after the addition of adiponectin to the cells, the level
of nuclear staining was abrogated by 70% (P,0.05). After
Adiponectin Effect on Prolyl-4-Hydroxylase
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was weak (P,0.05); the combination of WP631 and adiponectin
also showed weak staining in the nucleus (P,0.05), which confirms
the specificity of the Sp1 inhibitor used. However, staining for Sp1
in the nucleus was not influenced by adiponectin or WP631 alone
(P.0.05).
3.3 Effect of adiponectin on the expression of P4Ha1
Induced by IL-6 in HASMCs. IL-6 significantly downregulated
the level of P4Ha1 mRNA by 65% (P,0.05) and protein by 70%
(P,0.05) as compared with control cells (Fig. 3C,D). Eight hours
after the addition of adiponectin to the cells, the level of P4Ha1
mRNA was increased 5.8-fold (P,0.05) and that of P4Ha1
protein six-fold (P,0.05). After preincubation with WP631 for 1
hr or the Sp1 inhibitor WP631 and adiponectin combined, the
level of P4Ha1 mRNA and protein returned to the level of control
cells. However, the expression of P4Ha1 was not influenced by
adiponectin or WP631 alone (P.0.05).
4. ERK1/2 leads to adiponectin upregulating P4Ha1
expression in IL-6- mediated HASMCs in an
Sp1-dependent manner
4.1 Effect of adiponectin on phosphorylation of ERK
induced by IL-6 in HASMCs. IL-6 significantly induced the
phosphorylation of ERK in HASMCs as compared with control
cells (P,0.05) (Fig. 4A). Eight hours after the addition of
adiponectin to the cells, the phosphorylation of ERK induced by
IL-6 was abrogated by 70% (P,0.05). After preincubation with
PD98059 for 1 hr, the phosphorylation of ERK induced by IL-6
was abrogated by 95% (P,0.05). After preincubation with
PD98059 and adiponectin combined, the phosphorylation of
ERK induced by IL-6 was abrogated by 92% (P,0.05). However,
the phosphorylation of ERK was not influenced by adiponectin or
PD98059 alone (P.0.05).
4.2 Effect of ERK on Sp1 activation induced by IL-6 in
HASMCs. IL-6 significantly upregulated the binding activity of
Sp1 in HASMCs as compared with control cells (P,0.05) (Fig. 4B).
Eight hours aftertheaddition of adiponectinto thecells,the binding
activity ofSp1 induced byIL-6 was reduced by 70% (P,0.05).After
preincubation with PD98059 for 1 hr, the binding activity of Sp1
inducedbyIL-6 wasreducedby95%(P,0.05).Thecombination of
PD98059 and adiponectin reduced the IL-6-induced binding
activity of Sp1 by 93% (P,0.05). However, the binding activity of
Sp1 was not influenced by adiponectin or PD98059 alone (P.0.05).
4.3 Effect of ERK on subcellular localization and
expression of Sp1 induced by IL-6 in HASMCs. Most
unstimulated cells had diffuse staining in the cytoplasm, as well
as weak staining in the nucleus, under normal growth conditions
(Fig. 4C). With 1-h treatment with IL-6, staining for Sp1 in the
nucleus was increased seven-fold in HASMCs as compared with
control cells (P,0.05). Eight hours after the addition of
adiponectin, the level of nuclear staining was reduced by 70%
(P,0.05). After preincubation with PD98059 for 1 hr, the level of
nuclear staining was weak (P,0.05). The combination of
PD98059 and adiponectin also produced weak staining in the
nucleus (P,0.05). However, staining for Sp1 in the nucleus was
not influenced by adiponectin or PD98059 alone (P.0.05).
4.4 Effect of ERK on the expression of P4Ha1 induced by
IL-6 in HASMCs. IL-6 significantly downregulated the level of
Figure 1. Effect of dose and time of IL-6 treatment on P4Ha1 expression. (A and C) mRNA expression of P4Ha1. (B and D) Protein expression
of P4Ha1. Data are representative of 3 independent experiments (means6SD). *, p,0.05 vs. con.
doi:10.1371/journal.pone.0022819.g001
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HASMCs as compared with control cells (Fig. 4D,E). Eight hours
after the addition of adiponectin, the level of P4Ha1 mRNA was
increased 6.3-fold (P,0.05) and protein seven-fold (P,0.05). After
preincubation with PD98059 for 1 hr or the combination of
PD98059 and adiponectin, the level of P4Ha1 mRNA and protein
returned to the level of control cells (P,0.05). However, the
expression of P4Ha1 was not influenced by adiponectin or
PD98059 alone (P.0.05).
5. Effect of adiponectin overexpression on collagen
production
The content of procollagen I and III did not change significantly
with or without adiponectin or IL-6 treatment (Fig. 5A,B), whereas
after the addition of IL-6 to the cells, the content of collagen III
decreased significantly in HASMCs as compared with control cells
(IL-6:8.2060.3 mg/L vs. control: 12.160.1 mg/L; P,0.05)(Fig. 5D).
Eight hours after the addition of adiponectin to the cells, the content
of collagen III increased significantly (IL-6: 8.2060.3 mg/L vs. IL-
6+APN: 10.9760.2 mg/L; P,0.05) (Fig. 5D), whereas the content of
collagen I did not change significantly in all groups (Fig. 5C).
Discussion
Arterial interstitial collagen confers tensile strength on the
fibrous cap and thus determines plaque stability and vulnerability
to rupture. Therefore, the synthesis of collagen in the fibrous cap
may be directly responsible for plaque rupture[13]. In this study,
we aimed to investigate the role of ECM in the pathogenesis of
atherosclerosis and the potential mechanism of adiponectin
upregulating P4Ha expression in IL-6-stimulated HASMCs. First,
we determined that adiponectin can upregulate the expression of
P4Ha1 in HASMCs induced by IL-6. Second, we showed that
adiponectin upregulating P4Ha1 expression in IL-6-mediated
HASMCs depended in part on ERK1/2 activation and Sp1 DNA
binding activity. Adiponectin also increased collagen III level in
HASMCs alone with upregulated P4Ha1 expression.
Adiponectin is an adipose tissue-secreted protein with anti-
inflammatory and anti-atherogenic properties. A proinflammatory
state in adipose tissue can reduce secretion of adiponectin and
increase that of several cytokines, including TNFa, IL-6, and other
proinflammatory molecules [14]. Phosphorylation of GATA2 by
Akt increases adipose tissue differentiation and reduces adipose
tissue–related inflammation [15]. Other studies have investigated
the ratio of TNF to adiponectin and the consequences for
inflammation and atherosclerosis. Atherosclerosis was ameliorated
in gAd Tg apoE-deficient mice, which was associated with
decreased expression of class A scavenger receptor and TNFa
[16]. Full-length adiponectin was found to upregulate TNF-a and
IL-6 protein production differently [17]. In our research,
adiponectin attenuated the IL-6–inhibited P4Ha1 synthesis in
HASMCs and consequently changed the content of collagen. All
Figure 2. Effect of dose and time of adiponectin treatment on to P4Ha1 expression. (A and C) mRNA expression of P4Ha1. (B and D)
Protein expression of P4Ha1. Data are representative of 3 independent experiments (means6SD). *, p,0.05 vs. con; #, p,0.05 vs. IL-6.
doi:10.1371/journal.pone.0022819.g002
Adiponectin Effect on Prolyl-4-Hydroxylase
PLoS ONE | www.plosone.org 4 July 2011 | Volume 6 | Issue 7 | e22819of these data suggest the significant inverse relationship between
level of adiponectin and IL-6 or TNF-a associated with the
development of inflammation-related atherosclerosis. Although
adiponectin has anti-inflammatory and antiatherogenic properties,
it has no effect on normal cells, unless in combination with
inflammation. Adiponectin significantly suppressed LPS-induced
IL-6 and monocyte chemoattractant protein 1 production and also
significantly reduced NF-kappaB activity and IkappaB-alpha and
IKK gene expression as compared with 3T3-L1 induced by LPS
alone [18]. Adiponectin may reduce LPS-induced NO production
and nitrosative stress and prevent adventitial fibroblasts (AFs) from
proliferating, transforming to myoflbroblasts, and migrating to the
intima, thus worsening atherosclerosis, by inhibiting the AdipoR1-
AMPK-iNOS pathway in AFs [19]. Our present results also show
that adiponectin had no effect on P4Ha1 expression, Sp1 DNA
binding activity or ERK phosphorylation under basal conditions.
With IL-6 stimulation, adiponectin reverted the IL-6-induced
abnormal P4Ha1 expression, Sp1 DNA binding activity and ERK
phosphorylation to the normal level at least 2 times more than the
control. Therefore, adiponectin has anti-inflammatory properties
and might regulate inflammatory responses in atherosclerotic
lesions.
Several studies have identified that adiponectin might regulate
ECM metabolism in atherosclerotic lesions [20-22]. Our previous
study of an atherolerosis mouse model indicates that adiponectin
could significantly increase the expression of P4Ha1 in plaque,
Figure 3. Sp1 regulates the effect of adiponectin upregulating P4Ha1 expression in IL-6-mediated HASMCs. (A) Sp1 DNA binding
activity. (B) Subcellular localization of Sp1. (C) mRNA expression of P4Ha1. (D) Protein expression of P4Ha1. *, p,0.05 vs. con; #, p,0.05 vs. IL-6.
doi:10.1371/journal.pone.0022819.g003
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fibrous cap of atherosclerotic plaque and prevent plaque rupture
[23]. These data suggest that adiponectin might have anti-
atherosclerotic properties and regulate ECM metabolism in
atherosclerotic lesions, but the potential mechanism was unknown.
We further studied the regulation of adiponectin on P4Ha1
expression in vitro. The expression of P4Ha1 was mostly induced
by IL-6. Adiponectin could upregulate the expression of P4Ha1i n
HASMCs induced by IL-6 in a dose- and time-dependent manner,
so adiponectin might have anti-inflammatory properties and might
regulate ECM metabolism.
To identify signaling pathways in this induction, we studied the
activation of Sp1, a known transcriptional factor, that might play
an important role in the transcriptional regulation of ECM
metabolism [24–26]. IL-6, sIL-6R, or both were found to decrease
both the ratio of Sp1 to Sp3 and DNA binding activities, thus
inhibiting COL2A1 transcription [27]. Our results showed that
Sp1 DNA binding activity was enhanced on exposure to IL-6.
Both the mRNA and protein levels of P4Ha1 were significantly
attenuated. To clarify that the effect depended on Sp1, we used
the Sp1 inhbitor WP631, which efficiently inhibited Sp1 DNA
binding activity. In the presence of the inhibitor, P4Ha1 mRNA
and protein levels were significantly enhanced. Adiponectin could
counteract all of these effects. Therefore, Sp1 contributed to the
adiponectin-induced P4Ha1 expression.
MAPK pathways are important mediators of signal transduc-
tion and are involved in multiple intracellular signaling cascades
and activated by cytokines [28–31]. Some studies demonstrated
Figure 4. ERK1/2 leads to adiponectin upregulating P4Ha1 expression in IL-6-stimulated HASMCs. (A) p-ERK level. (B) Sp1 DNA-binding
activity. (C) Subcellular localization of Sp1. (D) mRNA expression of P4Ha1. (E) Protein expression of P4Ha1. *, p,0.05 vs. con; #, p,0.05 vs. IL-6.
doi:10.1371/journal.pone.0022819.g004
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involved in the ERK1/2 pathway [32–34]. Sp1, as a vital
downstream molecule in the MAPK pathway, can be activated by
ERK and induce the Sp1 DNA binding activity [35]. Our results
showed phosphorylation of ERK1/2 and Sp1 DNA binding
activity enhanced after exposure to IL-6. Both P4Ha1 mRNA and
protein levels were significantly attenuated. To clarify that the
effect depends on ERK1/2, we used the ERK1/2 inhbitor
PD98059, which efficiently inhibited phosphorylation of ERK1/2
and Sp1 DNA binding activity. In the presence of the inhibitor,
P4Ha1 mRNA and protein levels were significantly enhanced.
Adiponectin could counteract all of these effects. These results
supported that adiponectin upregulating P4Ha1 expression in IL-
6-mediated HASMCs depended in part on ERK1/2 activation.
The organic matrix of a plaque mainly consists of types I and III
collagen. Many studies have fully discussed their content and
changes in content in atherosclerotic plaques. The completely
processed and cross-linked type III collagen seems to be the major
collagen type in atherosclerotic plaques [36]. The density of type
III was increased in diabetes mellitus (DM) plaques with a non-
significant reduction in type I density in DM as compared with
non-DM plaques [37]. The pattern of GPVI-Fc binding was
similar to the immunostaining pattern of collagen type III but
differed from that of collagen type I, which was more intense in the
cap than in the core [38]. We further explored the effect of
adiponectin overexpression on collagen content and found no
difference in the content of procollagen I and III on IL-6
stimulation with or without adiponectin treatment; only collagen
III content was reversed by adiponectin. Therefore, type III
collagen seem to be the major collagen type in atherosclerotic
plaques. P4Ha1 is essential for collagen maturation and secretion
by folding the procollagen polypeptide chains into stable triple
helical molecules, so the change in collagen III content may reflect
the activity of P4Ha1 in HASMCs.
In conclusion, we show for the first time that adiponectin
attenuates the IL-6–inhibited P4Ha1 synthesis in HASMCs and
therefore collagen III content was changed. This effect of
adiponectin is through ERK1/2-dependent pathways and by
inhibiting Sp1 activation. Our results suggest that adiponectin may
play a major role in the development of the thick fibrous cap of
atherosclerotic plaque and stabilize plaque by increasing P4Ha1
synthesis in HASMCs stimulated by IL-6.
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